Menu
Washingtoner
  • Home
  • Health
  • Books
  • Business
  • Music
  • Construction
  • Artificial Intelligence
  • Technology
  • Publishing
Washingtoner

Allen Institute for Immunology and Seattle Children's Research Institute launch study to unravel molecular mysteries of pediatric IBD
Washingtoner/10257486

Trending...
  • Omnitronics launches Ecosystem Health Dashboard to enable proactive monitoring across dispatch environments
  • Tacoma: Applications Now Being Accepted for three Positions on the Urban Design Board
  • Independent West Texas Metal Multi-Instrumentalist & Producer. "MAD CHAD™" Russell Surpasses 1.9 Million Project Interactions Via DFGS Productions
SEATTLE, May 13, 2024 ~ Seattle, WA- With the number of pediatric inflammatory bowel disease (IBD) diagnoses increasing globally, a clinical trial in Seattle is aiming to revolutionize treatment approaches through deep molecular profiling. The Seattle STRIDE study, a collaboration between Seattle Children's Research Institute and the Allen Institute for Immunology, has begun recruiting volunteers for its three-year study.

The trial plans to enroll 200 participants and utilize genomic tools to analyze tissue samples from routine tests. These single-cell analysis methods will provide a detailed understanding of how the immune system behaves in patients with IBD and how it responds to specific drug treatments over time.

According to Dr. Betty Zheng, an assistant professor of pediatrics at Seattle Children's and the principal investigator of the study, this deep immune profiling could offer an unprecedented view of the disease and potentially lead to new and improved treatments.

"IBD is a complex disease and we still have a limited understanding of its molecular mechanisms," said Dr. Zheng. "By partnering with the Allen Institute, we hope to gain a detailed view of these mechanisms in order to find better ways of treating our patients."

More on Washingtoner
  • The City's Most Elegant Open-Air Dinner Party Returns September 12, 2026
  • Spokane: Incorrect Info Regarding Downgraded Evacuation Status on Popular App
  • FDA Clears Major Regulatory Hurdle as Preservative-Free Ketamine Program Moves Within Reach of Commercialization: NRx Pharmaceuticals: (NAS DAQ: NRXP)
  • Autonomous Robotics Platform Expansion as Public Market Debut is Very Close: MBody AI Corp. (N A S D A Q: MBAI)
  • Tacoma Voters Approve Connect Tacoma: Safe Streets and Sidewalks Levy (Proposition 1)

The exact causes and progression of IBD, a chronic inflammatory condition affecting the digestive tract, have remained elusive. It is believed that a combination of genetic factors, immune dysregulation, and environmental or dietary factors may play a role.

In children, IBD can be more aggressive and difficult to treat compared to adults. Approximately 30% of pediatric IBD patients do not respond to initial treatments and nearly half will eventually become resistant to their current treatments. This can lead to serious consequences such as impaired growth, mental health issues, and missed educational and social activities.

Dr. Zheng believes that a deeper understanding of the molecular workings of the disease could lead to personalized treatment strategies instead of relying on one-size-fits-all approaches.

"Some children respond well to first-line therapies while others require multiple treatments or do not respond at all," she explained. "This is a major challenge in the clinic."

In addition to potentially improving treatment options, a deep dive into the molecular mechanisms of IBD could also uncover new pathways of inflammation that could be targeted for the development of new drugs.

More on Washingtoner
  • Loud! OOH calls for prize draw advertising standards as £1.3bn category moves outdoors
  • Black Ribbon Productions Launches With Fearless 2026 Horror Slate
  • Spokane: Disaster Assistance Center will open Aug 6 at Shadle Park High School
  • Actor Dominic Pace Returns to Television and Film
  • Avenue Dental Care North Spokane Offers Free Emergency Care to Firefighters

Dr. Adam Savage, an assistant investigator at the Allen Institute for Immunology, emphasized the importance of exploring these unknown pathways.

"There is a universe of information that is not being seen," he said.

To uncover this information, Dr. Savage and his team will utilize advanced technologies developed at the Allen Institute for Immunology to identify and pinpoint immune cells and molecules within tissue samples collected during routine hospital visits. By analyzing these samples over time, they hope to gain insight into how the disease progresses and how patients respond to treatment.

While the study may involve complex data and advanced technologies, Dr. Savage reminds us that the ultimate goal is to improve the lives of patients.

"We may look at data on computers or work in labs, but when we see the patients we are trying to help, it serves as a powerful reminder of why we do what we do - to have a real impact on patients' lives," he said.

Families interested in participating in the Seattle STRIDE study can find more information on their website. The study offers hope for improved treatments and better outcomes for children with IBD.
Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on Washingtoner
  • Spokane: Wildfire and Insurance Informational Session
  • Premier Expands Presence with New Bellevue Flexible Workspace Location
  • Haven Treatment Center In-Network with MODA Health, Expanding Access to Behavioral Health
  • Cellofest Brings Free Cello Concerts and Community Events to Bethany Beach August 5–16
  • Blue Sky Capital Strategies, LLC awarded Leasing and Financial Services agreement with Premier Inc
  • Michael M. Thomas Expands Executive Leadership Across Central India Outreach and Royal Trinity School
  • Northeast Airlines and Travel, Inc. Initiates FAA Part 121 Certification for Boeing 737-800 Freighter Cargo Operations
  • Walker's Realty and North Jersey Properties Introduce Extraordinary Luxury Estate for Rent in West Orange, New Jersey
  • Extreme Heat Strains Home Appliances: Appliance EMT Offers "Summer Rescue" Relief
  • Independent West Texas Metal Multi-Instrumentalist & Producer. "MAD CHAD™" Russell Surpasses 1.9 Million Project Interactions Via DFGS Productions
  • No Download Needed: Goosechase Adds Browser Play to Every Experience
  • iCustoms launches iWarehouse, an AI bonded warehouse platform for customs and excise storage
  • Spokane: City Council Members Commends Unified Wildfire Response
  • National Night Out in Spokane Cancelled Due to Wildfire Conditions
  • Haven Treatment Center Achieves IMD Certification, Expanding Access to Residential Care
  • U.S.-Arab Trade Reaches $121.7 Billion, But the Stakes Are Rising
  • HER Patio Productions celebrates one-year Anniversary of "Say Grace"
  • Working Musicians Academy Partners with Black Dog Music Partners to Give Musicians Independent, Income-Producing Careers
  • Spokane: Community Resources Available to Those Impacted by Fires
  • Spokane Police Urge Public to Stay Out of Fire Evacuation Areas
_catLbl0 _catLbl1

Popular on Washingtoner

  • Martin A. Sumichrast Joins Hawkeye Systems, Inc. as Chairman of the Board - 106
  • Qscription Technologies Appoints Radiology Industry Veteran Elliot Silverman to Advisory Board
  • Spokane: Camp Sekani Update 7/9/26
  • Kolbus Introduces the Next Step in Casemaking Efficiency
  • MD Marine Electric Announces Rebranding as MD Electric Group
  • Florida Law Advisers, P.A. Named Best Divorce Firm of 2026 by Expert Law Attorneys
  • Sahar Education Invites You to Celebrate Afghan Culture and Community
  • Studica Robotics Supports Robotics Training Camp for WorldSkills Shanghai 2026
  • J. Kenton Pierce Wins Prometheus Award for Best Novel
  • Boston Industrial Solutions Launches New Citrine® SA1-370 Silicone Glue for Permanent Adhesion

Similar on Washingtoner

  • UK Financial Ltd Makes History: Chainlink CRE Circulating Supply Verification Goes Live Across Its Complete Ecosystem Of Nine Exchange-Traded Tokens
  • FDA Clears Major Regulatory Hurdle as Preservative-Free Ketamine Program Moves Within Reach of Commercialization: NRx Pharmaceuticals: (NAS DAQ: NRXP)
  • Autonomous Robotics Platform Expansion as Public Market Debut is Very Close: MBody AI Corp. (N A S D A Q: MBAI)
  • Why Baton Rouge's Humid Climate Can Contribute to Carpenter Ant Damage — J&J Exterminating Explains How to Protect Your Home
  • Expanding Beyond Space as New Drone Market Opportunities Accelerate Growth: Ascent Solar Technologies (N A S D A Q: ASTI)
  • Lauren Merrell, Dale Sorensen Real Estate, announces price improvement for an extraordinary island retreat
  • Qustone Launches Human-Centered Professional Network
  • Portalz Publishes FES World First Architecture Introducing a New Cryptographic Platform
  • Northeast Airlines and Travel, Inc. Initiates FAA Part 121 Certification for Boeing 737-800 Freighter Cargo Operations
  • U.S.-Arab Trade Reaches $121.7 Billion, But the Stakes Are Rising
Copyright © 2026 washingtoner.com | Terms of Service | Privacy Policy | Contact Us | Contribute